What’s on the Horizon: New Modalities & Promising Drug Classes 

A Special One-on-One Interview with a World Renowned Pioneer in GLP-1 Agonists

Glucagon-like peptide (GLP-1) agonists have taken the industry by storm with an unprecedented ascent and earning them a place among the industry’s blockbusters. How did this highly successful class of drugs come to fruition, what other opportunities exist, and what may be the next rising stars in the industry? 

To answer those all-important questions, DCAT is honored to host Dr. Richard DiMarchi, Ph.D., a globally renowned researcher and former Group Vice President at Eli Lilly and Company and Novo Nordisk, who is widely recognized for his pioneering work that laid the foundation for the development of GLP-1 agonists. 

Co-recipient of the 2024 Mani L. Bhaumik Breakthrough of the Year Award by the American Association for the Advancement of Science, former decade-long Chairman of the Peptide Therapeutics Foundation, co-founder of eight successful  biotech companies, and a widely recognized international authority on macromolecular medicines, Dr. DiMarchi will sit down for a one-on-one interview to share the development journey of GLP-1 agonists and his perspectives on the future of drug development with a focus on:  

• What new drug classes show the greatest promise and why? 

• How will new modalities, such as RNA therapeutics, cell & gene therapies, and other complex drugs factor into the industry’s pipeline and commercialization strategies? What are the challenges and opportunities?

• What place will traditional modalities—small molecules, monoclonal antibodies, or recombinant proteins—hold in the industry’s portfolios of the future? Is a re-balancing act in store?  

What’s your company’s strategy? Stay ahead of the curve and gain valuable insights to help align your company’s product and manufacturing strategies with the future of new product development. 

Speaker

• Richard DiMarchi, Ph.D., Distinguished Professor of Chemistry and the Gill Chair in Biomolecular Sciences, Indiana University and former Group Vice President, Eli Lilly and Company and Novo Nordisk

Price & Registration

DCAT Member Company Price: $49 

DCAT Week 2025 programs are exclusively available to registered DCAT Member Company employees. Confirm your company’s membership here or email DCATMembership@dcat.org.

The DCAT organization is pleased to offer timely and topical education sessions during DCAT Week. Compared to similar programs found in the industry’s marketplace, DCAT’s program fees are deeply discounted for employees of DCAT Member Companies. 

Who Should Attend?

• Bio/pharmaceutical companies, including individuals with functional responsibility in sourcing, procurement, supply management and external manufacturing.
• CDMOs/CMOs and suppliers (raw materials and other inputs), including individuals engaged in business development, sales, marketing and operational functions in support of bio/pharmaceutical development and manufacturing.
• Other companies engaged in the business of bio/pharmaceutical development and manufacturing.

Attending DCAT Week Programs

All materials provided to registrants (including slides, reports, and presented information) are only for their reference. Registrants may not copy, photograph, or redistribute any materials, and they are responsible for any claim for violations of copyright or other intellectual property rights.